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To date, the beta amyloid (Aβ) cascade hypothesis remains the main pathogenetic model of Alzheimer’s disease (AD), but its role
in the majority of sporadic AD cases is unclear. The “mitochondrial cascade hypothesis” could explain many of the biochemical,
genetic, and pathological features of sporadic AD. Somatic mutations in mitochondrial DNA (mtDNA) could cause energy failure,
increased oxidative stress, and accumulation of Aβ, which in a vicious cycle reinforce the mtDNA damage and the oxidative stress.
Despite the evidence of mitochondrial dysfunction in AD, no causative mutations in the mtDNA have been detected so far. Indeed,
resultsofstudiesontheroleofmtDNAhaplogroupsinADarecontroversial.Inthisreviewwediscusstheroleofthemitochondria,
and especially of the mtDNA, in the cascade of events leading to neurodegeneration, dementia, and AD.
Copyright © 2009 M. Mancuso et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Mitochondria are dynamic and pleomorphic organelles,
composed of a smooth outer membrane surrounding an
inner membrane of signiﬁcantly larger surface area that, in
turn,surroundsaprotein-richcore,thematrix.Theycontain
2to10moleculesofDNA,themitochondrialDNA(mtDNA)
[1]. Most likely, mitochondria are derived from aerobic
prokaryotes integrated into nucleated cells. Mitochondria
are ubiquitous in eukaryotes. Their number per cell ranges
from zero in erythrocytes to ten thousands in striated muscle
cells. Their main function is to support aerobic respiration
and to provide energy as adenosine triphosphate (ATP), by
means of the electron transport chain (ETC). The ETC is
needed for oxidative phosphorilation (which provides the
cell with the most eﬃcient energetic outcome in terms of
ATP production), and consists of four multimeric protein
complexes located in the inner mitochondrial membrane
[1]. The ETC also requires cytocrome c (cyt c)a n das m a l l
electron carrier, coenzyme Q10 (CoQ10, or ubiquinone).
Electrons are transported along the complexes to molecular
oxygen (O2), ﬁnally producing water. At the same time, pro-
tons are pumped across the mitochondrial inner membrane,
from the matrix to the intermembrane space, by complexes
I, III, and IV. This process creates an electrochemical proton
gradient. ATP is produced by the inﬂux of these protons
back through the complex V, or ATP synthase (the “rotary
motor”)[2].Thismetabolicpathwayisundercontrolofboth
nuclear (nDNA) and mitochondrial genomes [1, 3]. Other
functions concern mediation of cell death by apoptosis, heat
production by decoupling of the oxidative phosphorylation,
translation and transcription of mitochondrial genes [4].
In mitochondria, parts of some metabolic processes take
place, such as β-oxidation, citrate acid cycle, degradation
of aminoacids, haem biosynthesis, steroid metabolism, uric
acid cycle, and others.
The mtDNA is a 16.5-kb circular minichromosome built
up of complementary H- and L-strands [1]. The mitochon-
drial genome contains 37 genes, 13 of which encode for
subunits of ETC complexes, 22 for transfer RNAs (tRNAs),
and two for ribosomal RNAs (rRNAs) [1]. The 13 mtDNA-
encoded polypeptides are part of the respiratory system
and are assembled together with nuclear-encoded subunits.
SevenofthembelongtocomplexIorNADHdehydrogenase,
NADH:ubiquinone oxidoreductase (ND1, ND2, ND3, ND4,
ND4L, ND5, ND6), one to complex III or ubiquinol:
ferricytochrome c-oxidoreductase, three to complex IV or
cyt c oxidase (COX I, COX II, and COX III) and two
to complex V or ATP synthase (ATPase6 and ATPase8).
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subunits of complex II, are encoded by nDNA. mtDNA is
notprotectedbyhistones,itsmutationrateis10timeshigher
than that of nDNA, and it does not undergo recombination
during meiosis [5]. The mitochondrial genome is maternally
inherited.
Mitochondrial diseases (MD) are a group of disorders
causedbyimpairmentofthemitochondrialETC.Thegenetic
classiﬁcation of MD distinguishes disorders due to defects
in mtDNA from those due to defects in nDNA [3]. MtDNA
mutations are characterized by some peculiarities compared
to nDNA mutations, and can occur spontaneously or be
inherited from the mother. MtDNA mutations are classiﬁed
as either large-scale rearrangements (partial deletions or
duplications), usually sporadic, or point mutations, which
areusuallymaternallyinherited,andconcerngenesresponsi-
ble for protein synthesis (rRNAs or tRNAs), or genes encod-
ing subunits of the ETC [3]. The phenotypic expression
of mtDNA mutations depends on the aﬀected gene, its
tissue distribution, and the diﬀerent dependency of diﬀerent
organs and tissues on the mitochondrial energy supply. If
the load of mutant mitochondrial genomes exceeds a certain
amount in a given tissue, the eﬀect of the mutation can be
no longer compensated by wild-type mtDNA (“threshold
eﬀect”). Organs and tissues that predominantly rely on
mitochondrial aerobic energy production, such as visual and
auditory pathways, heart, central nervous system (CNS), and
skeletal muscle, are more frequently involved [1]. Phenotype
expression often require the inﬂuence of various factors,
such as nuclear modiﬁer genes, environmental inﬂuence
factors, or the presence of mtDNA polymorphisms. Clusters
ofmtDNAvariantsactaspredisposing haplotypesincreasing
the risk of disease [6].
Mitochondria play a central role in apoptotic cell death,
and mitochondrial dysfunction appears to have a certain
impact on the pathogenesis of several neurodegenerative
diseases, such as Alzheimer’s Disease (AD) [7]. In the past
twenty years research has been directed at clarifying the
involvement of mitochondria and defects in mitochondrial
oxidative phosphorylation in late-onset neurodegenerative
disorders. Morphological, biochemical, and genetic abnor-
malities of the mitochondria in several AD tissues have
been reported. Impaired mitochondrial respiration, partic-
u l a r l yC O X( c o m p l e xV )d e ﬁ c i e n c y ,h a sb e e no b s e r v e di n
brain, platelets, and ﬁbroblasts of AD patients [7]. The
“mitochondrial cascade hypothesis” [8] could explain many
of the biochemical, genetic, and pathological features of
sporadic AD. Somatic mutations in mtDNA could cause
energy failure, increased oxidative stress, and accumulation
of Aβ, which in a vicious cycle reinforces mtDNA damage
and oxidative stress (Figure 1). Despite the evidence of
mitochondrial dysfunction in AD, and despite the cognitive
impairment frequently reported in patients with mtDNA
mutation, no causative mutations in the mtDNA have been
linked to AD so far. Indeed, results of studies on the role
of mtDNA haplogroups in AD are controversial. Here, we
discuss the role of the mitochondria, and especially of
the mtDNA, in the cascade of events leading to AD, after




MD may aﬀect the only muscular tissue or present as a
multisystem disease [1]. One of the most frequently aﬀected
organs in mitochondrial diseases, in addition to the skeletal
muscle, is CNS, with a lot of diﬀerent possible manifesta-
tions, such as epilepsy, stroke-like episodes, ataxia, spasticity,
and dementia. MD associated with cognitive impairment
include mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes syndrome (MELAS), Kearns-Sayre
syndrome (KSS), Leigh syndrome, and many others [9]. At
the onset, cognitive impairment may be partial, appearing
with speciﬁc cognitive deﬁcits, particularly in abstract rea-
soning, verbal memory, visual memory, language (naming
and ﬂuency), executive or constructive functions, calcu-
lation, attention (attention deﬁcit disorder and decreased
attention span), or visuospatial functions [9–12]. Cognitive
functions and intellectual abilities may decline from initially
focal cognitive impairment to dementia [9–17]. Dementia
is deﬁned as chronic and disabling memory impairment,
with involvement of at least one other cognitive function,
resulting in reduced competence to judge or to reﬂect
[18]. Cognitive functions that can be involved are memory
for verbal and nonverbal materials, language, orientation,
constructional abilities, abstract thinking, problem solving,
or praxis. Changes in personality are often associated with
dementia, and also behavioral alteration may occur during
the evolution of the cognitive decline [19]. Diagnosis of
mitochondrialdementiarequiresneuropsychologicaltesting,
cerebrospinalﬂuidinvestigations, visually-evokedpotentials,
EEG, brain CT and MRI scans, phosphorus or proton-
magnetic resonance spectroscopy, SPECT, or positron emis-
sion tomography with ﬂuorine 18-labeled deoxyglucose
(FDG-PET) [18]. High-resolution regional cerebral blood
ﬂow obtained through Tc-99m ethylcysteinate dimer SPECT
can better localize and assess the extent of brain damage
in patients with suspected MD and only subtle changes on
MRI[20].Recently,reducedregionalglucosemetabolismhas
been observed in the frontotemporal region of two siblings
with mtDNA multiple deletions and a Mitochondrial neuro-
gastrointestinal encephalomyopathy (MNGIE)-like disorder,
by means of FDG-PET [21]. The discrepancy between the
absence of clinical and MRI signs of cerebral involvement
and the substantial impairment of glucose metabolism could
reﬂect a chronic subclinical encephalopathy [21].
In conclusion, pathogenic mutations in the mtDNA have
been found in patients with cognitive disorders. However,
little is known about whether pathogenic mtDNA mutations
and the resultant mitochondrial respiration deﬁciencies
contribute to the expression of cognitive alterations, such as
impairments of learning and memory. Recently Tanaka et
al. [22] used two groups of transmitochondrial mice (mito-
mice) with heteroplasmy for wild-type and pathogenically
deleted mtDNA. The “low” group carried 50% or less
of deleted mtDNA, whilst the “high” group carried more
than 50% of deleted mtDNA [22]. These authors observed
that deleted mtDNA load did not aﬀect learning and






















Figure 1: A proposed mechanism of mitochondrial induced cell death in Alzheimer’s disease. Legend: Aβ; amyloid-β; ROS reactive oxygen
species; ETC electron transport chain; mtPTP mitochondrial permeability transition pore; C cytochrome c; IMM inner mitochondrial
membrane; OMM outer mitochondrial membrane; APP amyloid precursor protein; TOM and TIM protein importation translocases of the
mitochondrialouterandinnermembranes.Forfurtherdetails,seetext.(ModiﬁedfromMancusoMetal.,AntioxidRedoxSignal2007;9:1631–
1646).
impairment of retention and consolidation of memory
trace [22]. In the visual cortex and dentate gyrus of these
mice have been reported respiratory system deﬁciencies, in
particular of COX activity [22]. Therefore, high loads of
pathogenicallymutatedmtDNA may be responsible forCOX
deﬁciency and for the preferential impairment of remote
memory.
Despite the cognitive impairment frequently reported in
MD patients, and despite the high prevalence of AD, AD
patients harbouring a mtDNA mutations have never been
reported.
3. Mitochondrial Dysfunction and
Alzheimer’sDisease
AD is the most common form of dementia in the elderly.
It is clinically characterized by impairment of cognitive
functions and changes in behavior and personality. AD is
associated with progressive and irreversible loss of neurons,
particularly in the cortex and hippocampus, extracellular
senile plaques containing aggregated Aβ, and neuroﬁbrillary
tangles composed of the hyperphosphorylated form of the
microtubular protein tau [23]. The Aβ cascade hypothesis
remains the main pathogenetic model of familial AD with
mutation in amyloid precursor protein (APP) and presenilin
genes [24], but its role in the majority of sporadic AD cases
without mutations in these genes (accounting for the great
majority of AD cases) is still unclear. The Aβ peptide is the
result of a regulated intramembrane proteolysis of APP by
the sequential cleavage by β-a n dγ-secretases [25, 26]. Aβ
plaques might be the cause of toxicity, loss of synapses, and
ultimately neuronal death [27, 28]. The exact mechanisms
of the neurotoxicity of Aβ are still unknown. Several lines
of evidence suggest that Aβ exerts its toxicity intracellularly
[29, 30], pointing to a role of the mitochondrion in this
process [31].
Mitochondrial dysfunction is a prominent feature of AD,
but the underlying mechanism is still unclear. Mitochondrial
Aβ accumulation impairs neuronal function contributing
to cellular dysfunction in a transgenic APP mouse model
[32]. During the early stages of AD a reduced number of
mitochondria in neurons has been reported [33], as well as
decreasedbrain glucose metabolism [34]. Moreover, reduced
activities of both tricarboxylic acid cycle enzymes [35]a n d
COX [36, 37]h a v eb e e nr e p o r t e d.
Because Aβ is not produced locally in the mitochondrion
[38, 39], Hansson Petersen et al. [40] recently investigated
the mechanism by which Aβ is taken up by mitochondria.
The most important system providing the translocation of
Aβ precursors with mitochondrial target signals involves
the translocase of the outer membrane (TOM) and the
translocase of the inner membrane (TIM). Targeting signals
are ﬁrst recognized by TOM receptors (Tom20, Tom22, and
Tom70), and then traslocated by Tom40, the general import
pore of TOM [41, 42]. Subsequently, Aβ precursors are
directed to the matrix via the Tim23 complex [42].
In isolated rat mitochondria has been observed that Aβ
is imported into mitochondria via the TOM complex [40].
Preincubatingmitochondriawithantibodiesdirectedtoward
Tom20, Tom40, or Tom70 clearly decreased the import of Aβ
[40]. The import into mitochondria was insensitive to the
mitochondrial membrane potential dissipater valinomycin,
indicating that it is independent of the mitochondrial
membrane potential [40].
Immunoelectron microscopy showed a consistent local-
ization pattern of Aβ to the mitochondrial cristae; the
integration of Aβ into the inner mitochondrial membrane,
site of ETC, is in line with results showing that Aβ may cause
inhibition of complex IV [43]. A similar labelling pattern
was obtained with immunoelectron microscopic analysis of
human brain biopsies [40].
Wang et al. [44] investigated the eﬀect of APP and
Aβ on mitochondrial dynamics in neurons. Confocal and4 International Journal of Alzheimer’s Disease
electron microscopic analysis demonstrated that about 40%
of neurons overexpressing wild type APP and more than
80% of cells overexpressing mutant APP displayed alter-
ations in mitochondrial morphology and distribution [44].
Speciﬁcally, mitochondria exhibited a fragmented structure
and an abnormal distribution accumulating around the
perinuclear area [44]. These mitochondrial changes were
abolished by treatment with β-site APP-cleaving enzyme
inhibitor IV [44]. From a functional perspective, APP
overexpression aﬀected mitochondria at multiple levels,
including elevating reactive oxygen species (ROS) levels,
decreasingmitochondrialmembranepotential,andreducing
ATP production, and also caused neuronal dysfunction [44].
Photoconvertible ﬂuorescence labelling technique showed
that mitochondria in APP-overexpressing cells were able
to fuse, but slower than controls. At the molecular level,
dynamin-like protein 1 (DLP1) was signiﬁcantly decreased,
as well as OPA1, the major organizer of the mitochondrial
inner membrane, required for the maintenance of cristae
integrity [44]. Overexpression of DLP1 in these cells rescued
the abnormal mitochondrial distribution and diﬀerentiation
deﬁciency, but failed to rescue mitochondrial fragmentation
and functional parameters [44]. On the other hand, overex-
pression of OPA1 rescued mitochondrial fragmentation and
functional parameters, but failed to restore normal mito-
chondrial distribution [44]. Overexpression of APP or Aβ-
derived diﬀusible ligand treatment also led to mitochondrial
fragmentation and reduced mitochondrial coverage in neu-
ronal processes [44]. Therefore APP overexpression, through
Aβ production, may perturb mitochondrial dynamics,
impacting mitochondrial function and neuronal function
[44]. These ﬁndings suggest that abnormal mitochondrial
dynamics could be involved in mitochondrial and neuronal
dysfunctions in AD patients, according with the decreased
number but increased size of mitochondria reported
in vulnerable neurons of human AD brain specimens
[33].
4. MitochondrialDNA Damage in
Alzheimer’sDisease
To explain the origin of the bioenergetic deﬁcits in AD, cell
depleted from endogenous mtDNA have been repopulated
with mitochondria (with their own mtDNA) from AD
patients and normal controls (cytoplasmic hybrid cells, or
“cybrids”) [45]. This application showed that the enzymatic
defects can be transferred to mtDNA-deﬁcient cells, thus
implicating mtDNA mutations [46]. AD cybrids showed also
overproduction of amyloidogenic Aβ peptides (1–40, 1–42),
accumulation of amyloid deposits similar to amyloid plaques
seen in AD brains, as well as major vulnerability to apop-
tosis [47]. The worsening of the bioenergetic impairment
occurred in long-term culture [48]. Although not all studies
with cybrid cells detected diﬀerences between AD patients
andcontrols[49],themajorityofthesedemonstratedsimilar
morphological and biochemical phenotype between cybrid
cells and cerebral tissue in sporadic AD, supporting the
hypothesis that mtDNA changes might be involved in the
mitochondrial impairment of sporadic AD. For a complete
discussion, see our recent review [7]. Therefore, it has been
speculated that aging-related mtDNA mutations may result
in impaired energy production, increased amount of ROS,
and cell damage, and subsequently neurodegeneration and
AD pathology (see Figure 1).
In AD brains, endothelial cells of vessels with atheroscle-
roticlesionsandnearbyperivascularcellshavebeenreported
to contain clusters of normal and deleted mitochondrial
genomes [50]. Chronic hypoperfusion may be an element
involved in the pathogenesis of AD, triggering oxidative
stress and mitochondrial dysfunction [51]. Aging and cere-
brovascular comorbidity could impair cerebral perfusion,
subsequently inducing brain capillary degeneration, and
suboptimal delivery of energy substrates to neuronal tissue
[52]. Mitochondrial dysfunction, oxidative stress, decreased
ATP production and increased calcium entry, abnormal pro-
tein synthesis, cell ionic pump deﬁciency, signal transduc-
tion defects, and neurotransmission failure resulting from
hypoperfusion may contribute to the progressive cognitive
decline characteristic of AD and neurodegeneration [50, 53].
In endothelial and perivascular cells of human AD brain
microvessels have been detected clusters of mitochondria-
derived lysosomes and necrotic changes. Ultrastructural
evaluations with probes for human normal and 5-kB deleted
mtDNA showed that in AD brain microvessels, but not in
age-matched control brains, were present mtDNA deletions
[54]. Immunocytochemical analysis demonstrated that the
mitochondrial abnormalities in neurons were associated
with increased markers of lipid peroxidation [54]. An
hypothetical sequence of events for AD progression may go
from oxidative damage (protein nitration, lipid peroxida-
tion, nDNA and mtDNA damage, RNA oxidation) to the
formation of preneuroﬁbrillary tangles inducing irreversible
neuronal damage [51].
Increased levels of 8-hydroxyguanosine (8-OHG), index
of mtDNA damage, have been reported in the hippocampus
and cerebral neocortex in AD, but not in the cerebellum
[55]. Interestingly, levels of 8-OHG were inversely related
to the amount of intracellular oligomeric forms of Aβ,
suggesting a complex interplay between ROS and Aβ [56].
MtDNA resulted to have approximately 10-fold higher
levels of oxidized bases than nDNA, that guanine is the
most vulnerable base to DNA damage, and that multiple
oxidizedbasesaresigniﬁcantlyhigherinADbrainspecimens
in comparison to controls [57]. Oxidative DNA damage
is repaired either in nuclei and in mitochondria by the
DNA base excision repair (BER) process [58]. Mitochondria
have an independent BER machinery, characterized by a
sequence of polymerase and ligase, whose reduction in
functionality has been reported in brains of patients with
AD, resulting in elevated levels of unrepaired mtDNA
[59].
5. Mitochondrial DNA Mutations in AD Brains
An increase of somatic mtDNA rearrangements has been
observed in AD brains. The mtDNA “common deletion” has
beenreportedtobeelevatedabout15-foldinADbrains[60].International Journal of Alzheimer’s Disease 5
Furthermore, the mtDNA A4336G transition was observed
more frequently in AD patients [61].
More recently, mtDNA control region (CR) mutations
have been reported as more frequent in AD brains than
in controls [62]. In particular, two heteroplasmic changes
were speciﬁc for AD brains (T414C and T477C) [62]. 65%
of the AD brains harboured the T414G mutation, whereas
this mutation was absent from in all control samples [62].
The mtDNA CR from patients and control brains has
been cloned and sequenced. AD brains had an average
63% increase in heteroplasmic mtDNA CR mutations (and
130% increase in patients older than 80 years) [62]. These
mutations preferentially altered known mtDNA regulatory
elements. The AD brains showed also an average 50%
reduction in mtDNA content and in the ND6 complex
I transcript, which may likely reduce the mitochondrial
oxidative phosphorylation [62].
On the other hand, another study involving a larger
number of tissue samples did not identify the T414C muta-
tion in AD brains [63]. Elson et al. sequenced the complete
coding regions of 145 autoptic AD brain samples and 128
normal controls, and observed that for both synonymous
and nonsilent changes the overall numbers of nucleotide
substitutionswerethesamefortheADandcontrolsequences
[64]. Therefore, no surely causative mtDNA mutations have
been reported in AD patients.
6.MitochondrialHaplogroupsand
Alzheimer’sDisease
The relatively rare familiar forms of AD are associated
with mutation in APP and presenilin genes. The causes of
sporadic form of AD, that constitutes the great majority of
the cases, are still unknown. The aetiology of sporadic AD is
multifactorial, involving environmental and genetic factors.
The major risk factor in sporadic AD is recognized in the
allele ε4 of apolipoprotein E (ApoE4).
Polymorphisms in mtDNA may cause diﬀerences in the
encoded proteins, resulting in changes in respiratory chain
activity and increasing free radicals. This may result in a
predisposition, for an individual or a population with the
same polymorphism, to develop early apoptotic processes,
accumulation of mitochondrial damages, and somatic DNA
mutations [65]. In mice, mtDNA polymorphism seem to be
involved in cognitive functioning [66].
The basal branching structure of mtDNA variation in
most parts of the world is now well understood [67]. African
haplogroups fall into seven major families (L0, L1, L2,
L3, L4, L5, L6). About 85 thousand years ago, probably
in the Horn of Africa, the root of haplogroup L3 gave
rise to many descendant haplogroups (probably because
of some colonization event or local population growth).
Non-African mtDNA descend from L3 and belong either
to the M or N superclades. In the Indian subcontinent
and in Southeast Asia there is the richest basal variation
in the three originated by haplogroups M and N, and this
suggests a rapid colonization along the southern coast of
Asia, about 60 thousand years ago [67]. The expansions
northwords occurred later, about 45 thousand years ago.
Over 30 subclades of the haplogroup M are present in
Asia. Haplogroups A, B, C, D, and X have been found
in the Americas, coming mainly from Asia. In Europeans
and Near Easterners (who share a rather recent common
ancestor) nine diﬀerent mitochondrial haplogroups have
been identiﬁed (H, I, J, K, T, U, V, W, X). The variation
in the basal European mtDNA haplogroups dates to about
45000 years ago. Complete mtDNA sequencing and the
increasing number of samples analyzed allow subdividing
haplogroups in smaller groups identifying younger branches
on the mtDNA evolution tree. Therefore, subhaplogroups
classiﬁcation is continuously evolving [67].
Speciﬁc mitochondrial haplogroups have been linked
to longevity [68–70]. Therefore, if they can be associated
with longevity, the same or other haplogroups could be
involved in neurodegeneration. Haplogroup distribution
has been reported to diﬀer between normal controls and
patients aﬀected with some neurodegenerative diseases, such
as Parkinson’s Disease [71]. Because of the sensitivity of
mtDNA as a marker for human migration patterns, all
studies of mtDNA haplogroup association with disease must
pay rigorous attention to the ethnic matching of cases to
controls [65].
The identiﬁcation of a possible role for mitochondrial
genomic dysfunction in AD, and at the same time the
unsuccessful research for mtDNA mutations in AD patients
[64], encouraged to study polymorphisms in mtDNA of
AD patients. The diﬀerent studies obtained contrasting
results. Chagnon et al. [72] reported that haplogroups T
was underrepresented in AD patients, and that haplogroups
J overrepresented. In an Italian sample of subject, instead,
haplogroupsKandUhadalowerfrequencyinapolipoprotein
(Apo)E4 carriers, whereasin control subjects this correlation
was not present [73]. Therefore, haplogroups K and U may
play a role in neutralizing the eﬀect of the major known AD
risk factor E4 allele [73]. van der Walt et al. reported that
haplogroup U in males was related to a signiﬁcant increase
in risk of developing AD, while in females seemed to be
associated to a signiﬁcant protection [74].
Very recently, Maruszak et al. [75] evaluated the involve-
ment of mitochondrial haplogroups, haplogroup clusters
(HV, UK, TJ, IWX) and of two functional mtDNA single
nucleotide polymorphism (mtSNPs 4216 and 4917) in
the pathogenesis of AD in the Polish population. These
authors observed that HV cluster seemed to be signiﬁcantly
associated with the risk of AD, regardless of the ApoE4
status [75]. The same study reported no evidence for the
involvement of haplogroup U, K, J, or T in AD risk [75]. Two
studies including only neuropathologically proven cases of
AD of European descent indicated that mtDNA haplogroups
were not associated with AD [64, 76].
A study performed in our laboratory evaluated the
frequency of the European mtDNA haplogroups in a clini-
cally well-deﬁned group of 209 unrelated patients and 191
controls, both with clear Tuscan origin, in order to minimize
the risk of false associations between gene markers and
disease [77]. The frequency of haplogroups H, I, J, K, T,
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patient and control groups, without signiﬁcant diﬀerence
between genders [77]. ApoE4 allele was signiﬁcantly more
frequent in patients than in controls, and was not associated
with any haplogroup [77]. Our data also excluded any
association between mtDNA haplogroups, age of onset and
mean survival [77].
7. Conclusion
The etiology of AD is complex, and only a minority of cases
appears to be primarily genetic. Changes of the expression of
mitochondrialandnucleargenes,encodingpartsofcytcoxidase
and NADH dehydrogenase enzyme complexes, may contribute
toalterationsofoxidativemetabolisminAD[78].Themajority
of cybrid studies demonstrated similar morphological and
biochemical phenotype between cybrid cells and cerebral tissue
insporadicAD,supportingthehypothesisthatmtDNAchanges
might be involved in the mitochondrial impairment of sporadic
AD. Although morphological, biochemical, and genetic
mitochondrial abnormalities have been clearly reported in
AD, the role of the mitochondrial genome and of its
haplogroups as a risk factor is still controversial. To date
no surely causative mtDNA mutations have been discovered
in AD patients. Also studies attempting to identify mtDNA
mutations in brains of AD patients obtained controversial
results. The mtDNA alterations that cybrid models induce to
hypothesize might be due to somatic factors, that is, cronic
hypoperfusion and oxidative damage.
MtDNA deletions themselves may contribute to aging,
dementia, and AD pathology, but the exact mechanism
of that is still unclear. Most likely, the mtDNA do not
play a primary role, and, therefore, it should be involved
subsequently(seeFigure 1).Indeed,theAPP“stocked”inthe
TOM transporters and the altered mitochondrial dynamics
seem pivotal, able to cause mitochondrial impairment,
respiratory deﬁciency and oxidative stress.
It will be important to develop a better understanding
of the role of oxidative stress and mitochondrial energy
metabolism in AD, and its link with the amyloid hypothesis
in aging and AD, since it may lead to the development
of more eﬀective treatment strategies for this devastating
disorder.
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